Collectively, the identification of hub targets of 18α-GA against NSCLC by network analysis and subsequent KEGG, GO, molecular docking, external expression analysis, and survival analysis verify the importance of particularly EGFR and AKT1 as the core therapeutic targets of 18α-GA among other hub genes. Here, EGFR is linked to non-small cell lung carcinoma.